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In hospitalised patients with COVID-19, an increase in oxygen requirements inevitably prompts the 
clinician to decide how and when to escalate treatment.  A key treatment goal is to, where possible, 
avoid the need for invasive mechanical ventilation (IMV).  However up to 20% of hospitalised 
patients in the UK require admission to critical care units, and around 40% of those requiring IMV for 
COVID-19 pneumonitis do not survive1.  To date, the only treatments that have been shown to 
reduce the need for invasive mechanical ventilation are dexamethasone and IL-6 blockade. 
 
The use of non-invasive respiratory support strategies such as continuous positive airway pressure 
(CPAP) or high-flow nasal oxygen (HFNO), are attractive treatment options which may avoid the 
need for IMV and its inherent risks.  In the context of COVID-19, concern has been raised that these 
strategies may cause harm to patients through delays to tracheal intubation or exacerbation of lung 
injury, to healthcare workers through nosocomial infection, and to healthcare systems through the 
high oxygen demand of devices.  
 
This uncertain balance of harms and benefits has resulted in marked variation in international 
practice.  A survey of 1132 participants across 85 countries used a case vignette of a previously 
healthy patient with severe hypoxaemia2; choice of initial oxygen strategy included high flow nasal 
oxygen (47%), CPAP or non-invasive ventilation (NIV) (26%), immediate tracheal intubation (7%), 
with remaining respondents opting to optimise conventional oxygen therapy.2  Variability in practice 
was associated with country, hospital rurality, ICU bed availability, and individual clinician 
characteristics.   
 
HFNO, CPAP, or NIV? 
There is a paucity of high-quality evidence for non-invasive respiratory support strategies in COVID-
19.  Direct evidence remains limited to retrospective case series and cohort studies with inconsistent 
findings and the inherent risk of bias associated with observational study design3-5.  For example a 
recent retrospective study reported failure rates of 66% in COVID-19 patients receiving CPAP, and 
high mortality (55%) in those requiring IMV after CPAP failure5.  Evidence for HFNO, CPAP, and NIV 
as effective treatments for acute hypoxemic respiratory failure (AHRF), are drawn from populations 
of patients without COVID-19.  For example, a recent systematic review and network meta-analysis 
concluded that NIV delivered by both helmet and mask interface reduced risk of all-cause mortality 
and tracheal intubation, and HFNO reduced the need for tracheal intubation6.  However, patient 
populations in included studies were those presenting with community-acquired pneumonia.  
COVID-19 is a novel disease and generalising data from other causes of AHRF is inherently 
problematic. 
 
In patients with viral influenzae and other coronaviruses, high failure rates of NIV in excess of 70% 
have been reported7 such that CPAP or HFNO may serve only to delay, rather than avoid, tracheal 
intubation.  A concern regarding NIV use in patients with more compliant lungs, is the potential for 
large tidal volume breathing to cause patient self-induced lung injury which has a similar 
pathogenesis to ventilator-induced lung injury.  However the converse argument, is that liberal use 
of tracheal intubation and mechanical ventilation in COVID-19 is likely to increase ventilator-
associated complications and mortality8. 
 
The risk of nosocomial COVID-19 transmission to healthcare workers delivering non-invasive 
respiratory support strategies centres on potential aerosol generation.  Early evidence from 
mechanistic evaluations of aerosol and droplet spread suggest the risks of non-invasive strategies 
are comparable to each other, and to standard oxygen therapy.  Generation of aerosols may be 
influenced by the device, settings and interface, but also other important patient-characteristics 
factors such as viral load, or coughing profile.  However, the lack of substantive evidence does not 
indicate an absence of risk.  Further research is needed to understand the risk to both healthcare 
workers and other patients. 
 
Conflicting guidelines 
International guidelines on the management of AHRF and the use of non-invasive respiratory 
strategies in the context of COVID-19 are prolific (Table 1).  In the UK, clinicians may be informed by 
NHS England and the respiratory and intensive care/anaesthesia communities, as well as global 
organisations.  Across guidelines, there is marked variability in transparency of development, 
process of synthesising evidence, and recommended approach.  For example, NHS England  
(https://www.nice.org.uk/Media/Default/About/COVID-19/Specialty-guides/specialty-guide-NIV-
respiratory-support-and-coronavirus.pdf) recommends CPAP as the preferred form of non-invasive 
respiratory support in COVID-19 and recommends against HFNO use based on perceived lack of 
efficacy, oxygen use, and potential infection transmission to healthcare workers.  In contrast, 
Surviving Sepsis Campaign guidelines (https://doi.org/10.1007/s00134-020-06022-5) support the use 
of HFNO, although it acknowledges that the strength of this recommendation is weak, based on low 
certainty evidence.  
 
The World Health Organization guidance (https://www.who.int/publications/i/item/clinical-
management-of-covid-19) adopts a balanced recommendation, including the use of all non-invasive 
respiratory support strategies justified by the lack of evidence base available for any individual one.  
Others, including the Australia and New Zealand Intensive Care Society (ANZICS), have moved away 
from a previous position of favouring one strategy over another, and now base their 
recommendations on living guidelines (www.covid19evidence.net.au) that currently suggest 
decisions regarding non-invasive respiratory support be based on risk assessment of the individual 
patient and healthcare setting, with an emphasis on reducing the risk of infection transmission to 
healthcare workers. 
 
What does this mean for the clinician? 
There is an urgent need for randomised controlled trials to evaluate the effectiveness of non-
invasive respiratory support strategies in COVID-19 patients.  At present, clinical practice is driven by 
personal preference and influence, prior experience, and potentially local availability of modalities 
influenced by logistical concerns in the context of oxygen supplies.  But against this backdrop of 
uncertain evidence on the safety, effectiveness, and optimal approach for AHRF management, it is 
essential for clinicians to demonstrate equipoise and randomise patients into available clinical trials 
in their healthcare jurisdictions.  As an example there have been a number of reports of 
pneumomediastinum and pneumothorax in patients with COVID-19, both in patients receiving 
standard oxygen therapy and in those receiving non-invasive respiratory support9.  These reports are 
a cause for concern, although due to their observational nature are confounded by many 
unmeasured factors.  As non-invasive respiratory support is currently being used as part of usual 
care in many settings in the absence of evidence of harm, such reports further support the need for 
randomised controlled trials of non-invasive respiratory support in COVID-19 compared to standard 
care.  Clinical trials of non-invasive respiratory support should exclude patients with a 
contraindication to non-invasive respiratory support and ensure data on harms, such as incidence of 
pneumomediastinum and pneumothorax, are reported. 
 
By far the largest trial in this area is the UK RECOVERY-Respiratory Support trial10, funded and 
prioritised by the National Institute for Health Research as an urgent public health study.  This 
adaptive, randomised controlled, multi-centre trial evaluates the effectiveness of HFNO or CPAP 
against standard oxygen therapy across hospitalised COVID-19 patients with AHRF, with a primary 
outcome of tracheal intubation or mortality within 30 days of randomisation.  As of February 2021, 
over 1200 patients have been randomised, and enrolment to the trial features in two UK guidance 
pathways (Table 1).   
During a pandemic, when the demand for critical care resources significantly exceeds the available 
capacity11, use of non-invasive respiratory support in an individual patient in the absence of 
established evidence may be viewed as the only possible treatment, particularly if there is no option 
to participate in a clinical trial.  However, where there are no critical care capacity issues and options 
to participation in a clinical trial do exist, clinicians should be mindful that provision of this treatment 
outside the rigorous infrastructure of randomised clinical trials represents random empirical care. In 
the event one of these interventions is shown to be beneficial, this approach will have delayed 
answering the urgent clinical question at hand.  In the event of an intervention showing no 
favourable effect (or worse, harm), clinicians will need to justify their continued use of that 
unproven treatment as part of usual care rather than within a trial framework, as well as their 
decision to deny patients the opportunity to participate in nationally prioritised research.  To 
understand the most effective non-invasive respiratory support strategy in COVID-19 requires an 
investigation of the relative benefits and harms to both the patient and the wider healthcare system 
and this can only be addressed through randomisation to clinical trials.  Only in this way will we 
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